23. HIV State of the Art
Thursday, October 27, 2016: 8:30 AM-10:00 AM
Room: 393-396

Learning Objectives:

At the conclusion of this session, participants will be able to:

  • describe advances in antiretroviral drug treatment options
  • identify the most appropriate antiretroviral therapy regimens for initial treatment and subsequent therapies for management of HIV infection in adultsĀ 
  • review comprehensive city and state wide strategies for HIV prevention, care and treatment with a goal of reducing new HIV infections to zero

Target Audience: Fellows, HIV clinicians, HIV specialists, Infectious diseases physicians, Members-in-training, Public health practitioners

Tracks: Adult ID, HIV-STD-TB

Moderators:  Pablo Tebas, MD, FIDSA, University of Pennsylvania and Ian Frank, MD, University of Pennsylvania School of Medicine

9:00 AM
9:30 AM
Ending the Epidemic
Demetre Daskalakis, MD, MPH

CME Credits: Maximum of 1.5 hours of AMA PRA Category 1 Credit™

ACPE Credits: ACPE 1.5 knowledge-based contact hours 0.15 of pharmacy CE

ACPE Number: 0221-9999-16-222-L02-P


P. Tebas, Merck: Consultant , Consulting fee
Glaxo: Adjudication Committe member , Consulting fee

I. Frank, Gilead Sciences: Scientific Advisor , Consulting fee
ViiV/GlaxoSmithKline: Grant Investigator , Grant recipient

See more of: Symposium

Findings in the abstracts are embargoed until 12:01 a.m. CDT, Wednesday Oct. 26th with the exception of research findings presented at the IDWeek press conferences.